Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial
Por:
Gridelli C, Ciuleanu T, Domine M, Szczesna A, Bover I, Cobo M, Kentepozidis N, Zarogoulidis K, Kalofonos C, Kazarnowisz A, Korozan M, de las Penas R, Majem M, Chella A, Griesinger F, Bournakis E, Sadjadian P, Kotsakis A, Chinet T, Syrigos K, Correale P, Gallou C, Jamet J, Vetsika E, Kosmatopoulos K, Georgoulias V, Vx 001 201 Trial Team
Publicada:
1 may 2020
Ahead of Print:
1 mar 2020
Resumen:
Background The cancer vaccine Vx-001, which targets the universal tumour antigen TElomerase Reverse Transcriptase (TERT), can mount specific Vx-001/TERT572 CD8 + cytotoxic T cells; this immune response is associated with improved overall survival (OS) in patients with advanced/metastatic non-small cell lung cancer (NSCLC). Methods A randomised, double blind, phase 2b trial, in HLA-A*201-positive patients with metastatic, TERT-expressing NSCLC, who did not progress after first-line platinum-based chemotherapy were randomised to receive either Vx-001 or placebo. The primary endpoint of the trial was OS. Results Two hundred and twenty-one patients were randomised and 190 (101 and 89 patients in the placebo and the Vx-001 arm, respectively) were analysed for efficacy. There was not treatment-related toxicity >grade 2. The study did not meet its primary endpoint (median OS 11.3 and 14.3 months for the placebo and the Vx-001, respectively; p = 0.86) whereas the median Time to Treatment Failure (TTF) was 3.5 and 3.6 months, respectively. Disease control for >6months was observed in 30 (33.7%) and 26 (25.7%) patients treated with Vx-001 and placebo, respectively. There was no documented objective CR or PR. Long lasting TERT-specific immune response was observed in 29.2% of vaccinated patients who experienced a significantly longer OS compared to non-responders (21.3 and 13.4 months, respectively; p = 0.004). Conclusion Vx-001 could induce specific CD8(+) immune response but failed to meet its primary endpoint. Subsequent studies have to be focused on the identification and treatment of subgroups of patients able to mount an effective immunological response to Vx-001.
Filiaciones:
Gridelli C:
SG Moscati Hosp, Avellino, Italy
Ciuleanu T:
Oncol I Chircuta, Cluz Napoca, Romania
Domine M:
Fdn Jimenez Diaz, Madrid, Spain
Szczesna A:
Mazowieckie Ctr, Otwock, Poland
Bover I:
Son Llatzer Hosp, Palma De Mallorca, Spain
Cobo M:
Hosp Reg Univ Malaga, Inst Invest Biomed IBIMA, Malaga, Spain
Kentepozidis N:
251 Gen Airforce Hosp, Athens, Greece
Zarogoulidis K:
Papanikolaou Gen Hosp, Exohi, Greece
Kalofonos C:
Univ Hosp Patras, Rion, Greece
Kazarnowisz A:
Oddzial Onkol Pododdziatem, Olsztyn, Poland
Korozan M:
Hosp Dutkiewicza SAC, Gdansk, Poland
de las Penas R:
Hosp Prov Castellon, Castellon de La Plana, Spain
Majem M:
Hosp Santa Creui St Pau, Barcelona, Spain
Chella A:
AOU Pisa Hosp, Pisa, Italy
Griesinger F:
Pius Hosp, Oldenburg, Germany
Bournakis E:
Univ Hosp Aretaieion, Athens, Greece
Sadjadian P:
Johannes Wesling Klinikum, Minden, Germany
Kotsakis A:
Univ Gen Hosp Larissa, Dpt Med Oncol, Larisa, Greece
Chinet T:
Hop Ambroise Pare, Boulogne, France
Syrigos K:
Gen Hosp Thorac Dis Sotiria, Athens, Greece
Correale P:
Univ Hosp Siena, Siena, Italy
Gallou C:
Vaxon Biotech, Paris, France
Jamet J:
Vaxon Biotech, Paris, France
Vetsika E:
Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
Kosmatopoulos K:
Vaxon Biotech, Paris, France
Georgoulias V:
Univ Gen Hosp Heraklion, Iraklion, Crete, Greece
|